Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum]

Sechi A, Dardis A, Bembi B. Ther Clin Risk Manag. 2016; 12:53–58.

On page 57, left column, line 22, the text “patients who result in poor metabolizers should not be treated with this drug” should have been “patients who result in CYP2D6 ultra-rapid metabolizers or who are indeterminate metabolizers should not be treated with this drug”.